GYC Nantong Guangyuan Chemical Co
also known as G
Vials tend to hold more than the label (median +10.0%); 2 of 77 vials were more than 10% under.
For research use only. VendorVerify sells nothing and takes no money from vendors. No affiliate links, no coupon codes, no paid rankings. How scores work
Every vial we have on file
- Within ±5% / purity 99%+
- 5–20% under, overfilled / purity 95–99%
- Failed: over 20% under, over 50% over, empty or under 95% pure
Dose vs label
75 vials measured · 2 emptyPurity
80 vials measured- Median purity
- 99.80%
- across 80 vials
- Median dose vs label
- +10.0%
- across 75 vials; + means more than the label
- Failed vials
- 3.8%
- 2 of 84 vials; the rate weights each lab report equally and recent reports more, as the score does
- Lab reports
- 46
- Dec 18, 2024 to Sep 28, 2026
Labs: Chromate, ILS Laboratories, Janoshik, Peptide Test, Vanguard Laboratory
Key facts
- VendorVerify holds third-party lab results for 84 GYC vials from 46 lab reports, dated Dec 2024 to Sep 2026.
- 2 of 84 GYC vials failed: empty, under 95% pure, more than 20% under the label or more than 50% over it.
- The median GYC vial tested at 99.80% purity across 80 vials with a purity result.
- The median GYC vial held +10.0% compared with its label across 75 vials where the lab measured the amount.
- Buyers have had 9 different compounds from GYC lab tested.
- GYC ranks #12 of 30 ranked vendors on the VendorVerify score.
- GYC vials on file were tested by Chromate, ILS Laboratories, Janoshik, Peptide Test, Vanguard Laboratory.
By peptide
| Peptide | Vials | Failed | Median purity | Median dose vs label | Dose vs label, −20% to +20% |
|---|---|---|---|---|---|
| Tirzepatide | 36 | 1 | 99.85% | +8.7% | |
| Retatrutide | 32 | 0 | 99.73% | +10.8% | |
| BPC-157 | 3 | 0 | 99.28% | — | — |
| Cagrilintide | 3 | 0 | 99.84% | +16.3% | |
| Tesamorelin | 3 | 0 | 99.68% | +16.2% | |
| NAD+ | 2 | 0 | — | +11.1% | |
| Semaglutide | 2 | 0 | 99.88% | +9.1% | |
| SS-31 | 2 | 1 | 98.75% | +13.5% | |
| KLOW | 1 | 0 | 99.50% | — | — |
Lab reports
One row per tested vial, newest first.
| Date | Peptide | Lab | Label | Measured | Dose vs label | Purity |
|---|---|---|---|---|---|---|
| Sep 28, 2026 | RetatrutideBatch 2026061215 | ILS Laboratories | 15 mg | 15.37 mg | +2.5% | 99.29% |
| Sep 15, 2026 | KLOWBatch 206076380 | Vanguard Laboratory | 80 mg | — | — | 99.50% |
| Aug 21, 2026 | RetatrutideBatch 2026061230 | Janoshik | 30 mg | 33.18 mg | +10.6% | 99.62% |
| Aug 12, 2026 | RetatrutideBatch 2026061215 | Janoshik | 15 mg | 16.65 mg | +11.0% | 99.01% |
| Aug 10, 2026 | TirzepatideBatch 20260601030 | Janoshik | — | 32.78 mg | — | 99.67% |
| May 27, 2026 | RetatrutideBatch 2026031230 RT30 (Purple Cap) | Peptide Test | 30 mg | 36.516 mg | +21.7% | 99.88% |
| Apr 28, 2026 | RetatrutideBatch 2026031220 | Janoshik | 20 mg | 21.75 mg | +8.8% | 99.86% |
| Apr 28, 2026 | RetatrutideBatch 2026031220 | Janoshik | 20 mg | 21.75 mg | +8.8% | 99.85% |
| Apr 16, 2026 | RetatrutideBatch 2026031210 | Janoshik | 10 mg | 11 mg | +10.0% | 99.69% |
| Apr 16, 2026 | RetatrutideBatch 2026031210 | Janoshik | 10 mg | 10.99 mg | +9.9% | 99.65% |
Other lab tests
Endotoxin, TFA, counterion and contaminant checks, as reported by the lab. They are shown for transparency and are not part of the score.
| Date | Peptide | Test | Result | Lab |
|---|---|---|---|---|
| Sep 28, 2026 | RetatrutideBatch 2026061215 | Endotoxin | 0.087 EU/mL | ILS Laboratories |
| Sep 15, 2026 | KLOWBatch 206076380 | Endotoxin | 7.59 EU/mg | Vanguard Laboratory |
| Aug 20, 2026 | RetatrutideBatch 2026061230 | Endotoxin | <1 EU/Vial. | Janoshik |
| Aug 11, 2026 | RetatrutideBatch 2026061215 | Endotoxin | 8.280 EU/Vial. | Janoshik |
| Aug 10, 2026 | TirzepatideBatch 20260601030 | Endotoxin | 17.116 EU/Vial | Janoshik |
| Jul 18, 2026 | TirzepatideBatch 2026021020 20 mg | Endotoxin | <10 EU/Vial (2.197 EU/Vial estimate) | Janoshik |
| Jun 22, 2026 | TirzepatideBatch GYC 2026031030 T-30 (Orange Cap) | Endotoxin | 2.022 EU/Vial. | Janoshik |
| Jun 6, 2026 | RetatrutideBatch R10 2026041210 | Endotoxin | 57.403 EU/Vial. | Janoshik |
| Apr 27, 2026 | TirzepatideBatch GYC T6 2026021060 | Endotoxin | 13.410 EU/Vial | Janoshik |
| Apr 27, 2026 | RetatrutideBatch 2026031220 | Endotoxin | <10 EU/Vial (3.214 EU/Vial estimate) | Janoshik |
GYC: common questions
Is GYC legit?
We can't vouch for any vendor as a business, and we don't sell or recommend products. What we can show is what buyers' independent lab tests found: 2 of 84 GYC vials on file failed, meaning they were empty, under 95% pure, more than 20% under the label or more than 50% over it. That places GYC #12 of 30 ranked vendors, at market on our score. Results on file run from Dec 2024 to Sep 2026.
Has GYC been third-party tested?
Yes. We hold results for 84 GYC vials from 46 lab reports, tested by Chromate, ILS Laboratories, Janoshik, Peptide Test, Vanguard Laboratory. Each result comes from a lab report a buyer paid for, not from a certificate the vendor supplied.
Are GYC vials dosed correctly?
Across 75 vials where the lab measured the amount, the median GYC vial held +10.0% compared with its label. 2 of 77 held more than 10% less than the label said.
How pure is GYC?
The median GYC vial tested at 99.80% purity across 80 vials with a purity result. We count anything under 95% as a failed vial, and a vial at 99.5% or higher gets full marks for purity.
Does GYC pay to be listed or ranked?
No. VendorVerify sells nothing and takes no money from vendors. No affiliate links, no coupon codes, no paid rankings. A vendor's place comes only from lab results.
Will my GYC vial match these results?
Not necessarily. A lab report describes the vials that were tested, and batches differ. A clean record lowers the odds of a bad vial but doesn't rule one out, which is why newer reports count for more in the score.
Vendor Reviews
Bought from this vendor?
Sign in to write a review. Every review comes from a verified phone number and a real purchase.